US Patent Issued to BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY on May 13 for "CD19-based chimeric antigen receptor and application thereof" (Chinese Inventor)

ALEXANDRIA, Va., June 12 -- United States Patent no. 12,297,288, issued on May 13, was assigned to BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY Co. LTD. (Beijing).

"CD19-based chimeric antigen receptor and application thereof" was invented by Rui Zhang (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application provides a chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises an antigen-binding domain, a transmembrane domain, a costimulatory signal transduction region, a CD3Zeta signal transduction domain, and an inducible suicide fusion domain in tandem arrangement; wherein the antigen-binding domain binds to a tumor surface antigen and the tumor surface ...